Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Switch to Aromasin Maintains QOL of Breast Cancer Patients: IES Study
March 6, 2006
- Pfizer Japan to Appoint New President & CEO
March 6, 2006
- R&D NEWS IN BRIEF
March 6, 2006
- GSK to Participate in Vaccine Business in Japan
March 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
March 6, 2006
- MPC, Lequio Pharma License Zione to Yuhan of South Korea
March 6, 2006
- 47 Chemotherapy Specialists to Be Certified by JSMO in April
March 6, 2006
- Chugai Licenses Conditionally Immortalized Cell Line from Cambrex
March 6, 2006
- NEW BOOKS
March 6, 2006
- Kyowa Hakko Licenses Parkinson's Treatment from Britannia
March 6, 2006
- Japanese Branch of RAPS Established
March 6, 2006
- Fresenius to Complete Seamless Production System for Dialyzers in Japan
February 27, 2006
- Korosho's NHI Pricing Reform Proposals Approved
February 27, 2006
- GSK Distributes Asthma Control Test to Physicians for Use by Patients
February 27, 2006
- JGPMA Holds Symposium, Panel Discussion on GE Drug Quality
February 27, 2006
- R&D NEWS IN BRIEF
February 27, 2006
- Nearly All Dispensing Pharmacies Handle Generic Drugs: Survey
February 27, 2006
- PMDA Providing More Multiple Preliminary Interviews
February 27, 2006
- 33% of Patients Requested Generic Substitution, 18% Received Generics: Survey
February 27, 2006
- Systems Drug Discovery Should Replace Probabilistic Drug Discovery: Prof. Tanuma
February 27, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…